Cognitive Protective Effect of Newer Antidiabetic Drugs

Sponsor
Alexandria University
Study ID
NCT05347459
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin — DRUG
    usual and customary doses for type 2 diabetes management
  • Empagliflozin — DRUG
    usual and customary doses for type 2 diabetes management
  • Canagliflozin — DRUG
    usual and customary doses for type 2 diabetes management
  • Sitagliptin — DRUG
    usual and customary doses for type 2 diabetes management
  • Saxagliptin — DRUG
    usual and customary doses for type 2 diabetes management
  • Linagliptin — DRUG
    usual and customary doses for type 2 diabetes management
  • Vildagliptin — DRUG
    usual and customary doses for type 2 diabetes management

Study Details

The proposed study aims to: 1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria 2. Examine the possible relationship of such effects with the systemic inflammatory and metabolic status in these patients 3. Undertake a network analysis to elucidate the potential pathways linking the observed protective effects, if any, with the observed changes in inflammatory or metabolic parameters

Key Dates

Start date
Mar 2, 2022
Status verified
Jul 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: New Antidiabetic
    Type 2 diabetic patients receiving SGLT2 inhibitors and/or DPP-4 inhibitors with metformin
  • Arm: Traditional Antidiabetic
    Type 2 diabetic patients treated with metformin
  • Arm: Control
    Healthy non-diabetic patients

Primary Outcome Measure

Prevention of decline in cognitive function associated with type 2 diabetes [ Time Frame: 1 Year ]

Central Contacts

Related Studies